Automated Machine Learning for Predicting Diabetic Retinopathy Progression From Ultra-Widefield Retinal Images.


Journal

JAMA ophthalmology
ISSN: 2168-6173
Titre abrégé: JAMA Ophthalmol
Pays: United States
ID NLM: 101589539

Informations de publication

Date de publication:
01 Mar 2024
Historique:
pmc-release: 08 02 2025
pubmed: 8 2 2024
medline: 8 2 2024
entrez: 8 2 2024
Statut: ppublish

Résumé

Machine learning (ML) algorithms have the potential to identify eyes with early diabetic retinopathy (DR) at increased risk for disease progression. To create and validate automated ML models (autoML) for DR progression from ultra-widefield (UWF) retinal images. Deidentified UWF images with mild or moderate nonproliferative DR (NPDR) with 3 years of longitudinal follow-up retinal imaging or evidence of progression within 3 years were used to develop automated ML models for predicting DR progression in UWF images. All images were collected from a tertiary diabetes-specific medical center retinal image dataset. Data were collected from July to September 2022. Automated ML models were generated from baseline on-axis 200° UWF retinal images. Baseline retinal images were labeled for progression based on centralized reading center evaluation of baseline and follow-up images according to the clinical Early Treatment Diabetic Retinopathy Study severity scale. Images for model development were split 8-1-1 for training, optimization, and testing to detect 1 or more steps of DR progression. Validation was performed using a 328-image set from the same patient population not used in model development. Area under the precision-recall curve (AUPRC), sensitivity, specificity, and accuracy. A total of 1179 deidentified UWF images with mild (380 [32.2%]) or moderate (799 [67.8%]) NPDR were included. DR progression was present in half of the training set (590 of 1179 [50.0%]). The model's AUPRC was 0.717 for baseline mild NPDR and 0.863 for moderate NPDR. On the validation set for eyes with mild NPDR, sensitivity was 0.72 (95% CI, 0.57-0.83), specificity was 0.63 (95% CI, 0.57-0.69), prevalence was 0.15 (95% CI, 0.12-0.20), and accuracy was 64.3%; for eyes with moderate NPDR, sensitivity was 0.80 (95% CI, 0.70-0.87), specificity was 0.72 (95% CI, 0.66-0.76), prevalence was 0.22 (95% CI, 0.19-0.27), and accuracy was 73.8%. In the validation set, 6 of 9 eyes (75%) with mild NPDR and 35 of 41 eyes (85%) with moderate NPDR progressed 2 steps or more were identified. All 4 eyes with mild NPDR that progressed within 6 months and 1 year were identified, and 8 of 9 (89%) and 17 of 20 (85%) with moderate NPDR that progressed within 6 months and 1 year, respectively, were identified. This study demonstrates the accuracy and feasibility of automated ML models for identifying DR progression developed using UWF images, especially for prediction of 2-step or greater DR progression within 1 year. Potentially, the use of ML algorithms may refine the risk of disease progression and identify those at highest short-term risk, thus reducing costs and improving vision-related outcomes.

Identifiants

pubmed: 38329765
pii: 2814752
doi: 10.1001/jamaophthalmol.2023.6318
pmc: PMC10853872
doi:

Types de publication

Journal Article Comment

Langues

eng

Sous-ensembles de citation

IM

Pagination

171-177

Subventions

Organisme : Medical Research Council
ID : MR/R025630/1
Pays : United Kingdom

Commentaires et corrections

Type : CommentOn

Auteurs

Paolo S Silva (PS)

Beetham Eye Institute, Joslin Diabetes Center, Boston, Massachusetts.
Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts.

Dean Zhang (D)

Beetham Eye Institute, Joslin Diabetes Center, Boston, Massachusetts.

Cris Martin P Jacoba (CMP)

Beetham Eye Institute, Joslin Diabetes Center, Boston, Massachusetts.
Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts.

Ward Fickweiler (W)

Beetham Eye Institute, Joslin Diabetes Center, Boston, Massachusetts.
Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts.

Drew Lewis (D)

Estenda Solutions, Conshohocken, Pennsylvania.

Jeremy Leitmeyer (J)

Estenda Solutions, Conshohocken, Pennsylvania.

Katie Curran (K)

Centre for Public Health, Queen's University Belfast, Belfast, United Kingdom.

Recivall P Salongcay (RP)

Centre for Public Health, Queen's University Belfast, Belfast, United Kingdom.

Duy Doan (D)

Beetham Eye Institute, Joslin Diabetes Center, Boston, Massachusetts.

Mohamed Ashraf (M)

Beetham Eye Institute, Joslin Diabetes Center, Boston, Massachusetts.
Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts.

Jerry D Cavallerano (JD)

Beetham Eye Institute, Joslin Diabetes Center, Boston, Massachusetts.
Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts.

Jennifer K Sun (JK)

Beetham Eye Institute, Joslin Diabetes Center, Boston, Massachusetts.
Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts.

Tunde Peto (T)

Centre for Public Health, Queen's University Belfast, Belfast, United Kingdom.

Lloyd Paul Aiello (LP)

Beetham Eye Institute, Joslin Diabetes Center, Boston, Massachusetts.
Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts.

Classifications MeSH